Recent Updates
Recently added Catalysts
HSIC Positive Sentiment

Applied BioCode Announces Distribution Agreement with Henry Schein

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Applied BioCode has entered into a distribution agreement with Henry Schein to enhance the availability of its BioCode® MDx-3000 System. This automated platform is designed for high-complexity clinical laboratories and includes a comprehensive molecular diagnostics menu. The partnership aims to improve access to advanced diagnostic testing.

Market Sentiment Analysis

POSITIVE FACTORS

  • New distribution agreement expands product availability.
  • Collaboration with a leading healthcare provider.
  • Enhances access to advanced molecular diagnostics.

Full Press Release Details

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to expand the availability of its BioCode® MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode® MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal

Frequently Asked Questions

What is the BioCode® MDx-3000 System?

The BioCode® MDx-3000 System is an automated, high-throughput multiplex molecular diagnostic platform.

Who is Henry Schein?

Henry Schein is a leading provider of healthcare products and services.

What does the distribution agreement entail?

The agreement aims to expand the availability of the BioCode® MDx-3000 System.

What types of tests does the MDx-3000 include?

The MDx-3000 includes tests for upper respiratory and gastrointestinal conditions.

ShareAdd on Google
Tags: HSIC Viatris Investor Conferences Healthcare Applied BioCode Henry Schein molecular diagnostics clinical laboratories
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$157M liquidity · $0M/mo burn
Low dilution risk